Helus Pharma Advances Anxiety Treatment with Promising Clinical Data

A significant clinical milestone has been reached in the treatment of generalized anxiety disorder (GAD), a condition affecting over 20 million adults in the United States. Helus Pharma, the company formerly known as Cybin, has reported encouraging Phase 2 trial results for its drug candidate HLP004, targeting patients who do not respond to standard antidepressant therapies. This development marks the first potential new monotherapy for GAD in nearly two decades.

Clinical Efficacy and Tolerability

The Phase 2 study demonstrated substantial efficacy for HLP004. Patients who continued to exhibit symptoms despite conventional treatment received a 20-milligram dose of the investigational drug as an adjunctive therapy. After six weeks, data showed an average reduction of 10.4 points on the Hamilton Anxiety Rating Scale.

The long-term data further highlighted the compound’s potential. At the six-month follow-up, 67% of trial participants were classified as responders, with 39% achieving remission. The serotonergic agonist was reported to be well-tolerated, with no serious drug-related adverse events observed. The acute effects of the medication were noted to subside approximately 90 minutes after administration.

Corporate Strategy and Financial Positioning

This clinical progress coincides with a period of strategic corporate evolution for the biotechnology firm. In January, the company rebranded to Helus Pharma and completed a transfer of its listing from the NYSE American to the Nasdaq exchange.

Should investors sell immediately? Or is it worth buying Cybin?

To support its operational growth, the company this week appointed Jill Conwell as its Chief People Officer. Her primary mandate is to develop organizational structures in preparation for a potential future product launch. Financially, Helus is well-capitalized for its next phase. A recently closed financing round added $175 million to its treasury. This brings the company’s pro forma cash and equivalents to $248 million, a position strengthened by the concurrent retirement of outstanding convertible notes.

Pipeline Development and Upcoming Catalysts

Building on the success of HLP004, investor attention is now turning to the company’s second major pipeline asset. HLP003, a drug candidate being developed as an adjunctive treatment for major depressive disorder, has already received Breakthrough Therapy designation from the U.S. Food and Drug Administration. A Phase 3 trial for this program is currently enrolling patients across 45 sites in the United States.

The company anticipates reporting critical topline data from this Phase 3 study in the fourth quarter of 2026. Alongside an established manufacturing partnership with Thermo Fisher, these forthcoming results are expected to form the foundational framework for Helus Pharma’s corporate development throughout the current year.